|
18 Companies |
|
27 Products |
|
27 Products |
|
52 Mechanisms of Action |
|
0 Trials |
|
55 News |
|
| 12» |
- | Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: PACE4 in Thyroid Cancer (clinicaltrials.gov) - Oct 2, 2018
P=N/A, N=39, Completed, Sponsor: Robert Day
Enrolling by invitation --> Completed | N=30 --> 39 | Trial completion date: Oct 2017 --> Jan 2018 | Trial primary completion date: Jul 2017 --> Jan 2018
- | Trial termination: Iodine I 131 in Treating Patients With Thyroid Cancer (clinicaltrials.gov) - Jul 18, 2018
P=N/A, N=9, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrolling by invitation --> Completed | N=30 --> 39 | Trial completion date: Oct 2017 --> Jan 2018 | Trial primary completion date: Jul 2017 --> Jan 2018 Completed --> Terminated; Study was terminated due to loss of funding.
- | Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - Apr 3, 2018
P2, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Study was terminated due to loss of funding. Active, not recruiting --> Completed
- | Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment closed, Trial primary completion date, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - Aug 22, 2017
P2, N=25, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jul 2015
- | thalidomide / Generic mfg.
Trial completion: Thalidomide in Treating Patients With Thyroid Cancer (clinicaltrials.gov) - Jun 6, 2017
P2, N=0, Completed, Sponsor: Kenneth Ain
Suspended --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jul 2015 Active, not recruiting --> Completed
- | gefitinib / Generic mfg.
Enrollment change, Metastases: Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy (clinicaltrials.gov) - May 31, 2017
P2, N=27, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed N=38 --> 27
- | Biomarker, New trial: PACE4 in Thyroid Cancer (clinicaltrials.gov) - May 18, 2017
P=N/A, N=30, Enrolling by invitation, Sponsor: Robert Day
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial primary completion date, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - Dec 23, 2016
P2, N=25, Suspended, Sponsor: National Cancer Institute (NCI)
N=38 --> 27 Trial primary completion date: Aug 2016 --> Jun 2017
- | gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy (clinicaltrials.gov) - Nov 4, 2016
P2, N=38, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Aug 2016 --> Jun 2017 Active, not recruiting --> Completed
- Trial primary completion date, MRI: Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=20, Suspended, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Apr 2015
- Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Enrollment change, Combination therapy, Surgery, Metastases: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 9, 2015
P1, N=6, Completed, Sponsor: University of Washington
Trial primary completion date: Dec 2015 --> Apr 2015 Active, not recruiting --> Completed | N=24 --> 6
- sunitinib / Generic mfg.
Trial completion, Metastases: Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov) - Sep 30, 2015
P2, N=35, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed | N=24 --> 6 Active, not recruiting --> Completed
- Trial suspension, MRI: Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study (clinicaltrials.gov) - Jun 23, 2015
P=N/A, N=20, Suspended, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Recruiting --> Suspended
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial suspension, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=25, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Recruiting --> Suspended
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Trial primary completion date, Metastases: Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) - Jun 3, 2015
P2, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Oct 2012
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=40, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Oct 2012 Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Oct 2014
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, Metastases: Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) - Nov 19, 2014
P2, N=41, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Oct 2014 Trial primary completion date: Jun 2014 --> Mar 2015
- decitabine / Generic mfg.
Trial completion, Enrollment change, Metastases: Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 (clinicaltrials.gov) - Sep 4, 2014
P2, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Mar 2015 Active, not recruiting --> Completed | N=40 --> 12
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial primary completion date, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - Aug 27, 2014
P2, N=25, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=40 --> 12 Trial primary completion date: Sep 2014 --> Aug 2016
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Epigenetic controller, Metastases: Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer (clinicaltrials.gov) - Aug 11, 2014
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2014 --> Aug 2016 N=25 --> 19
- bortezomib / Generic mfg.
Enrollment change, Metastases: Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) - Jun 27, 2014
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=25 --> 19 N=45 --> 24
- bortezomib / Generic mfg.
Trial completion, Enrollment change, Metastases: Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) - Jun 27, 2014
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=45 --> 24 Active, not recruiting --> Completed | N=45 --> 24
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, Metastases: Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) - May 5, 2014
P2, N=41, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=45 --> 24 Trial primary completion date: Apr 2014 --> Jun 2014
- sunitinib / Generic mfg.
Trial primary completion date, Metastases: Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov) - May 4, 2014
P2, N=35, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Apr 2014 --> Jun 2014 Trial primary completion date: Jul 2013 --> May 2015
- tanespimycin (BMS-722782) / BMS
Enrollment change, Metastases: Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Apr 3, 2014
P2, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2013 --> May 2015 N=72 --> 41
- tanespimycin (BMS-722782) / BMS
Trial completion, Metastases: Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Apr 3, 2014
P2, N=41, Completed, Sponsor: National Cancer Institute (NCI)
N=72 --> 41 Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Combination therapy, Surgery, Metastases: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 20, 2014
P1, N=24, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | celecoxib oral / Generic mfg.
Trial completion, IO biomarker, Metastases: Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=25, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | semaxanib (SU5416) / Pfizer
Trial completion, Metastases: SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck (clinicaltrials.gov) - Feb 19, 2014
P1, N=12, Completed, Sponsor: Case Comprehensive Cancer Center
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (clinicaltrials.gov) - Feb 19, 2014
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | azacitidine / Generic mfg.
Trial completion, Metastases: Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Lucille P. Markey Cancer Center at University of Kentucky
Active, not recruiting --> Completed No longer recruiting --> Completed
- Istodax (romidepsin) / Astellas, BMS
Enrollment change, Metastases: Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine (clinicaltrials.gov) - Oct 28, 2013
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed N=41 --> 20
- | Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion: A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors (clinicaltrials.gov) - Sep 16, 2013
P1, N=40, Completed, Sponsor: Exelixis
N=41 --> 20 Active, not recruiting --> Completed
- MRI: Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study (clinicaltrials.gov) - Aug 21, 2013
P=N/A, N=20, Recruiting, Sponsor: Massachusetts General Hospital
- sorafenib / Generic mfg.
Trial termination, Metastases: Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer (clinicaltrials.gov) - Jun 2, 2013
P2, N=25, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial initiation date, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - May 14, 2013
P2, N=25, Recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Initiation date: Nov 2012 --> May 2013
- Enrollment change: Iodine I 131 in Treating Patients With Thyroid Cancer (clinicaltrials.gov) - May 14, 2013
P=N/A, N=9, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Nov 2012 --> May 2013 N=96 --> 9
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment open, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - May 14, 2013
P2, N=25, Recruiting, Sponsor: National Cancer Institute (NCI)
N=96 --> 9 Not yet recruiting --> Recruiting
- Trial completion: Iodine I 131 in Treating Patients With Thyroid Cancer (clinicaltrials.gov) - May 14, 2013
P=N/A, N=9, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Completed
- decitabine / Generic mfg.
Enrollment closed, Metastases: Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 (clinicaltrials.gov) - Mar 31, 2013
P2, N=37, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Suspended --> Active, not recruiting
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
New P2 trial, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - Mar 12, 2013
P2, N=25, Recruiting, Sponsor: National Cancer Institute (NCI)
- everolimus / Generic mfg.
Enrollment change, Metastases: Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Feb 25, 2013
P2, N=40, Recruiting, Sponsor: Yonsei University
Suspended --> Active, not recruiting N=32 --> 40
- bortezomib / Generic mfg.
Enrollment closed, Metastases: Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) - Feb 11, 2013
P2, N=45, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=32 --> 40 Recruiting --> Active, not recruiting
- gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 10, 2013
P=N/A, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Terminated --> Completed
- Caprelsa (vandetanib) / Sanofi
Enrollment change, Combination therapy, Metastases: S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 14, 2012
P1, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Terminated --> Completed N=60 --> 0
- Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment change, Metastases: NGR-TNF in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 19, 2012
P1, N=70, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=60 --> 0 N=30 --> 70
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Metastases: NGR-TNF in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 19, 2012
P1, N=70, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=30 --> 70 Active, not recruiting --> Completed
- |||| motesanib (AMG 706) / Takeda
Trial completion, Metastases: A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Sep 16, 2012
P2, N=184, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- tanespimycin (BMS-722782) / BMS
Enrollment closed, Metastases: Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Aug 20, 2012
P2, N=72, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Active, not recruiting